Breast carcinoma with brain metastases: Clinical analysis and immunoprofile on tissue microarrays

Annals of Oncology

Volumn 22, Issue 12, 2011, Pages 2597-2603

  Brogi, E ^a   Murphy, C G ^a   Johnson, M L ^a   Conlin, A K ^a   Hsu, M ^a   Patil, S ^a   Akram, M ^a   Nehhozina, T ^a   Jhaveri, K L ^a   Hudis, C A ^a   Seidman, A D ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Basal breast carcinoma; Cytokeratin 5 6; EGFR; Estrogen receptor; HER2; Triple negative

Indexed keywords

CYTOKERATIN 5; CYTOKERATIN 6; TUMOR MARKER;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BRAIN METASTASIS; BREAST CARCINOMA; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER SURVIVAL; CARCINOGENESIS; CARCINOMA; CLINICAL ASSESSMENT; CLINICAL FEATURE; DISEASE ASSOCIATION; HUMAN; HUMAN TISSUE; IMMUNOASSAY; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RETROSPECTIVE STUDY; SURVIVAL RATE; TISSUE MICROARRAY;

ADULT; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; BREAST NEOPLASMS; CARCINOMA; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; KERATIN-5; KERATIN-6; MIDDLE AGED; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 82355169099     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr022     Document Type: Article

References (39)

1. Mayer M. A patient perspective on brain metastases in breast cancer. Clin Cancer Res 2007; 13: 1623-1624.
2. Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer. J Clin Oncol 2004; 22: 3608-3617.
3. Altundag K, Bondy ML, Mirza NQ et al. Clinicopathologic characteristics and prognostic factors in 420 metastatic breast cancer patients with central nervous system metastasis. Cancer 2007; 110: 2640-2647.
4. Duchnowska R, Dziadziuszko R, Czartoryska-Arlukowicz B et al. Risk factors for brain relapse in HER2-positive metastatic breast cancer patients. Breast Cancer Res Treat 2009; 117: 297-303.
5. Lee SS, Ahn JH, Kim MK et al. Brain metastases in breast cancer: prognostic factors and management. Breast Cancer Res Treat 2008; 111: 523-530.
6. Ogawa K, Yoshii Y, Nishimaki T et al. Treatment and prognosis of brain metastases from breast cancer. J Neurooncol 2008; 86: 231-238.
7. Ryberg M, Nielsen D, Osterlind K et al. Predictors of central nervous system metastasis in patients with metastatic breast cancer. A competing risk analysis of 579 patients treated with epirubicin-based chemotherapy. Breast Cancer Res Treat 2005; 91: 217-225.
8. Tham YL, Sexton K, Kramer R et al. Primary breast cancer phenotypes associated with propensity for central nervous system metastases. Cancer 2006; 107: 696-704.
9. Wolff AC, Hammond MEH, Schwartz JN et al. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. Journal of Clinical Oncology 2007; 25: 118-145.
10. Paget S. The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev 1989; 8: 98-101.
11. Pestalozzi BC, Zahrieh D, Price KN et al. Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol 2006; 17: 935-944.
12. Graesslin O, Abdulkarim BS, Coutant C et al. Nomogram to predict subsequent brain metastasis in patients with metastatic breast cancer. J Clin Oncol 2010; 28: 2032-2037.
13. Hicks DG, Short SM, Prescott NL et al. Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR. Am J Surg Pathol 2006; 30: 1097-1104.
14. Clark GM, Sledge GW Jr., Osborne CK, McGuire WL. Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients. J Clin Oncol 1987; 5: 55-61.
15. Evans AJ, James JJ, Cornford EJ et al. Brain metastases from breast cancer: identification of a high-risk group. Clin Oncol (R Coll Radiol) 2004; 16: 345-349.
16. Slimane K, Andre F, Delaloge S et al. Risk factors for brain relapse in patients with metastatic breast cancer. Ann Oncol 2004; 15: 1640-1644.
17. Miller KD, Weathers T, Haney LG et al. Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival. Ann Oncol 2003; 14: 1072-1077.
18. Carey LA, Ewend MG, Metzger R et al. Central nervous system metastases in women after multimodality therapy for high risk breast cancer. Breast Cancer Res Treat 2004; 88: 273-280.
19. Palmieri D, Smith QR, Lockman PR et al. Brain metastases of breast cancer. Breast Dis 2006; 26: 139-147.
20. Arik Z, Dogan E, Aksoy S, Altundag K. Long-term survivors among breast cancer patients with brain metastases. Ann Oncol 2010; 21: 1128.
21. Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747-752.
22. Livasy CA, Karaca G, Nanda R et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 2006; 19: 264-271.
23. Nielsen TO, Hsu FD, Jensen K et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004; 10: 5367-5374.
24. Moriya T, Kozuka Y, Kanomata N et al. The role of immunohistochemistry in the differential diagnosis of breast lesions. Pathology 2009; 41: 68-76.
25. Mahler-Araujo B, Savage K, Parry S, Reis-Filho JS. Reduction of E-cadherin expression is associated with non-lobular breast carcinomas of basal-like and triple negative phenotype. J Clin Pathol 2008; 61: 615-620.
26. Rakha EA, Abd El Rehim D, Pinder SE et al. E-cadherin expression in invasive non-lobular carcinoma of the breast and its prognostic significance. Histopathology 2005; 46: 685-693.
27. Ribeiro-Silva A, Ramalho LN, Garcia SB et al. p63 correlates with both BRCA1 and cytokeratin 5 in invasive breast carcinomas: further evidence for the pathogenesis of the basal phenotype of breast cancer. Histopathology 2005; 47: 458-466.
28. Gaedcke J, Traub F, Milde S et al. Predominance of the basal type and HER-2/neu type in brain metastasis from breast cancer. Mod Pathol 2007; 20: 864-870.
29. Slamon DJ, Godolphin W, Jones LA et al. Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. Science 1989; 244: 707-712.
30. Bendell JC, Domchek SM, Burstein HJ et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 2003; 97: 2972-2977.
31. Dawood S, Broglio K, Esteva FJ et al. Survival among women with triple receptor-negative breast cancer and brain metastases. Ann Oncol 2009; 20: 621-627.
32. Lin NU, Claus E, Sohl J et al. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer 2008; 113: 2638-2645.
33. Cleator S, Heller W, Coombes RC. Triple-negative breast cancer: therapeutic options. Lancet Oncol 2007; 8: 235-244.
34. Bhargava R, Beriwal S, Striebel JM, Dabbs DJ. Breast cancer molecular class ERBB2: preponderance of tumors with apocrine differentiation and expression of basal phenotype markers CK5, CK5/6, and EGFR. Appl Immunohistochem Mol Morphol 2010; 18: 113-118.
35. Luck AA, Evans AJ, Green AR et al. The influence of basal phenotype on the metastatic pattern of breast cancer. Clin Oncol (R Coll Radiol) 2008; 20: 40-45.
36. Bos PD, Zhang XH, Nadal C et al. Genes that mediate breast cancer metastasis to the brain. Nature 2009; 459: 1005-1009.
37. Klein A, Olendrowitz C, Schmutzler R et al. Identification of brain- and bonespecific breast cancer metastasis genes. Cancer Lett 2009; 276: 212-220.
38. Kennecke H, Yerushalmi R, Woods R et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol 2010.
39. Martin B, Aragues R, Sanz R et al. Biological pathways contributing to organ-specific phenotype of brain metastatic cells. J Proteome Res 2008; 7: 908-920.